{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:18:59Z","timestamp":1792509539559,"version":"4.5.0"},"reference-count":26,"publisher":"American Medical Association (AMA)","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2003,6,4]]},"abstract":"Context<\/jats:title>Standard therapy for hot flashes has been hormone replacement with estradiol or progestational agents, but recent data suggest that antidepressants inhibiting serotonin reuptake may also be effective.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate a selective serotonin reuptake inhibitor (paroxetine controlled release [CR]) in treating the vasomotor symptoms displayed by a general cross-section of menopausal women.<\/jats:p><\/jats:sec>Design and Setting<\/jats:title>Randomized, double-blind, placebo-controlled, parallel group study conducted across 17 US sites, including urban, suburban, and rural clinics.<\/jats:p><\/jats:sec>Patients<\/jats:title>A total of 165 menopausal women aged 18 years or older experiencing at least 2 to 3 daily hot flashes and must have discontinued any hormone replacement therapy for at least 6 weeks. Women were excluded if they had any signs of active cancer or were undergoing chemotherapy or radiation therapy.<\/jats:p><\/jats:sec>Intervention<\/jats:title>After a 1-week placebo run-in phase, study participants were randomized to receive placebo or receive 12.5 mg\/d or 25.0 mg\/d of paroxetine CR (in a 1:1:1 ratio) for 6 weeks.<\/jats:p><\/jats:sec>Main Outcome Measures<\/jats:title>Mean change from baseline to week 6 in the daily hot flash composite score (frequency \u00d7 severity).<\/jats:p><\/jats:sec>Results<\/jats:title>Fifty-six participants were randomly assigned to receive placebo and 51 to receive 12.5 mg\/d and 58 to receive 25.0 mg\/d of paroxetine CR. The mean reductions in the hot flash frequency composite score from baseline to week 6 were statistically significantly greater for those receiving paroxetine CR than for those receiving placebo. By week 6, the mean daily hot flash frequency went from 7.1 to 3.8 (mean reduction, 3.3) for those in the 12.5-mg\/d and from 6.4 to 3.2 (mean reduction, 3.2) for those in the 25-mg\/d paroxetine CR groups and from 6.6 to 4.8 (mean reduction, 1.8) for those in the placebo group. Mean placebo-adjusted reduction in hot flash composite scores were \u22124.7 (95% confidence interval, \u2212 8.1 to \u22121.3; P<\/jats:italic> = .007) comparing 12.5-mg\/d paroxetine CR with placebo; and \u22123.6 (95% confidence interval, \u22126.8 to \u22120.4; P<\/jats:italic> = .03) comparing 25.0-mg\/d paroxetine CR with placebo. This corresponded to median reductions of 62.2% for those in the 12.5-mg\/d and 64.6% for those in the 25.0-mg\/d paroxetine CR groups compared with 37.8% for those in the placebo group.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>Paroxetine CR may be an effective and acceptable alternative to hormone replacement and other therapies in treating menopausal hot flash symptoms.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jama.289.21.2827","type":"journal-article","created":{"date-parts":[[2003,6,4]],"date-time":"2003-06-04T02:04:30Z","timestamp":1054692270000},"page":"2827","source":"Crossref","is-referenced-by-count":425,"title":["Paroxetine Controlled Release in the Treatment of Menopausal Hot Flashes"],"prefix":"10.1001","volume":"289","author":[{"given":"Vered","family":"Stearns","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine L.","family":"Beebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malini","family":"Iyengar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Dube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"ref-joc22297-1","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial.","volume":"288","author":"Writing Group for the Women's Health Initiative Investigators","year":"2002","journal-title":"JAMA"},{"key":"ref-joc22297-2","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/0531-5565(94)90012-4","article-title":"Hot flashes: phenomenology, quality of life, and search for treatment options.","volume":"29","author":"Kronenberg","year":"1994","journal-title":"Exp Gerontol"},{"key":"ref-joc22297-3","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/nyas.1990.592.issue-1","article-title":"Hot flashes: epidemiology and physiology.","volume":"592","author":"Kronenberg","year":"1990","journal-title":"Ann N Y Acad Sci"},{"key":"ref-joc22297-5","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1093\/jnci\/88.21.1529","article-title":"Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.","volume":"88","author":"Fisher","year":"1996","journal-title":"J Natl Cancer Inst"},{"key":"ref-joc22297-6","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.","volume":"90","author":"Fisher","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"ref-joc22297-7","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1200\/JCO.2001.19.7.1885","article-title":"Tamoxifen for the prevention of breast cancer: psychosocial impact on women participating in two randomized controlled trials.","volume":"19","author":"Fallowfield","year":"2001","journal-title":"J Clin Oncol"},{"key":"ref-joc22297-8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJM199408113310602","article-title":"Megestrol acetate for the prevention of hot flashes.","volume":"331","author":"Loprinzi","year":"1994","journal-title":"N Engl J Med"},{"key":"ref-joc22297-10","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1200\/JCO.2002.20.6.1578","article-title":"Phase III evaluation of fluoxetine for treatment of hot flashes.","volume":"20","author":"Loprinzi","year":"2002","journal-title":"J Clin Oncol"},{"key":"ref-joc22297-11","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(00)03403-6","article-title":"Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial.","volume":"356","author":"Loprinzi","year":"2000","journal-title":"Lancet"},{"key":"ref-joc22297-12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1023\/A:1008382706068","article-title":"A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors.","volume":"11","author":"Stearns","year":"2000","journal-title":"Ann Oncol"},{"key":"ref-joc22297-13","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/S0140-6736(02)11774-0","article-title":"Hot flushes.","volume":"360","author":"Stearns","year":"2002","journal-title":"Lancet"},{"key":"ref-joc22297-14","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1200\/JCO.1998.16.2.495","article-title":"Prospective evaluation of vitamin E for hot flashes in breast cancer survivors.","volume":"16","author":"Barton","year":"1998","journal-title":"J Clin Oncol"},{"key":"ref-joc22297-15","doi-asserted-by":"publisher","first-page":"577","DOI":"10.4088\/JCP.v63n0707","article-title":"Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression.","volume":"63","author":"Golden","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"ref-joc22297-16","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.","volume":"59","author":"Sheehan","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"ref-joc22297-17","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/archpsyc.1961.01710120031004","article-title":"An inventory for measuring depression.","volume":"4","author":"Beck","year":"1961","journal-title":"Arch Gen Psychiatry"},{"key":"ref-joc22297-18","doi-asserted-by":"publisher","first-page":"4280","DOI":"10.1200\/JCO.2001.19.23.4280","article-title":"Methodologic lessons learned from hot flash studies.","volume":"19","author":"Sloan","year":"2001","journal-title":"J Clin Oncol"},{"key":"ref-joc22297-19","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1200\/JCO.1994.12.1.155","article-title":"Transdermal clonidine for ameliorating tamoxifen-induced hot flashes.","volume":"12","author":"Goldberg","year":"1994","journal-title":"J Clin Oncol"},{"key":"ref-joc22297-20","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1093\/aje\/152.5.463","article-title":"Relation of demographic and lifestyle factors to symptoms in a multi-racial\/ethnic population of women 40-55 years of age.","volume":"152","author":"Gold","year":"2000","journal-title":"Am J Epidemiol"},{"key":"ref-joc22297-21","first-page":"505","article-title":"Serotonin and thermoregulation: old and new views.","volume":"77","author":"Myers","year":"1981","journal-title":"J Physiol (Paris)"},{"key":"ref-joc22297-22","doi-asserted-by":"publisher","first-page":"R1260","DOI":"10.1152\/ajpcell.1998.274.4.C855","article-title":"Changes in extracellular serotonin in rat hypothalamus affect thermoregulatory function.","volume":"274","author":"Lin","year":"1998","journal-title":"Am J Physiol"},{"key":"ref-joc22297-23","doi-asserted-by":"publisher","first-page":"3949","DOI":"10.1097\/00001756-200012180-00009","article-title":"Temperature set-point changes induced by DA D2\/3 and 5-HT1A receptor agonists in the rat.","volume":"11","author":"Oerther","year":"2000","journal-title":"Neuroreport"},{"key":"ref-joc22297-24","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/0028-3908(86)90101-2","article-title":"Thermoregulatory responses to serotonin (5-HT) receptor stimulation in the rat: evidence for opposing roles of 5-HT2 and 5-HT1A receptors.","volume":"25","author":"Gudelsky","year":"1986","journal-title":"Neuropharmacology"},{"key":"ref-joc22297-25","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0006-3223(98)00162-0","article-title":"Estrogen-serotonin interactions: implications for affective regulation.","volume":"44","author":"Rubinow","year":"1998","journal-title":"Biol Psychiatry"},{"key":"ref-joc22297-26","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/S0006-3223(99)00266-8","article-title":"Neural circuits mediating stress.","volume":"46","author":"Lopez","year":"1999","journal-title":"Biol Psychiatry"},{"key":"ref-joc22297-4","volume-title":"Resident Population Estimates of the United States by Age and Sex: April 1, 1990 to July 1, 1999, with Short-Term Projection to November 1, 2000","author":"US\u00a0Census Bureau","year":"2001"},{"key":"ref-joc22297-9","unstructured":"North American Menopausal Society. Amended report from the NAMS advisory panel on postmenopausal hormone therapy. Available at: http:\/\/www.menopause.org\/news.html_advisory. Accessed November 2002."}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/196678\/joc22297_2827_2834_1704911606.82517.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T19:00:34Z","timestamp":1704913234000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/196678"}},"subtitle":["A Randomized Controlled Trial"],"short-title":[],"issued":{"date-parts":[[2003,6,4]]},"references-count":26,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2003,6,4]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.289.21.2827","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2003,6,4]]}}}